We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 05, 2021

First-Line Afatinib + Cetuximab for EGFR-Mutant NSCLC

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
First-Line Afatinib Plus Cetuximab for EGFR-Mutant Non-Small-Cell Lung Cancer: Results From the Randomized Phase 2 IFCT-1503 ACE-Lung Study
Clin. Cancer Res 2021 May 24;[EPub Ahead of Print], AB Cortot, A Madroszyk-Flandin, E Giroux Leprieur, O Molinier, E Quoix, H Berard, J Otto, I Rault, D Moro-Sibilot, J Raimbourg, E Amour, F Morin, J Hureaux, L Moreau, D Debieuvre, H Morel, A Renault, E Pichon, B Huret, S Charpentier, MG Denis, J Cadranel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading